English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, June 22, 2018
Eisai Selected for Membership in MSCI Japan Empowering Women Index (WIN)
アッヴィとエーザイ、ヒト型抗ヒトTNFαモノクローナル抗体「ヒュミラ(R)」の新たな小児用製剤「ヒュミラ(R)皮下注20mgシリンジ0.2mL」を発売
エーザイ、「MSCI日本株女性活躍指数(WIN)」の構成銘柄に選定
Thursday, June 21, 2018
AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL
Thursday, June 14, 2018
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Nucleic Acid Drug Discovery Research
Wednesday, June 13, 2018
エーザイ、新規の核酸合成とデリバリー技術を用いた核酸創薬研究に関する産学官共同研究開発契約を締結し、研究活動を開始
Eisai to Establish New Research Facility "Eisai Center for Genetics Guided Dementia Discovery" in Cambridge, Massachusetts, USA
エーザイ、米国マサチューセッツ州ケンブリッジに新たな研究所Eisai Center for Genetics Guided Dementia Discoveryを設立
Monday, June 11, 2018
アッヴィ・エーザイ・EAファーマ、ヒト型抗ヒトTNFαモノクローナル抗体「ヒュミラ(R)」とオート・インジェクター製剤「ヒュミラ(R)皮下注ペン」を新発売
AbbVie and Eisai Announce the Launch of HUMIRA Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA

Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: